key: cord-0898014-02w7o1qv authors: Kovacs, Laszlo; Kress, Taylor C.; Belin de Chantemèle, Eric J. title: HIV, Combination Antiretroviral Therapy, and Vascular Diseases in Men and Women date: 2022-01-19 journal: JACC Basic Transl Sci DOI: 10.1016/j.jacbts.2021.10.017 sha: b2135d7a7072e043102f18d384de232f3f3c6df2 doc_id: 898014 cord_uid: 02w7o1qv Thanks to the advent of combination antiretroviral therapy (cART), people living with human immunodeficiency virus (HIV) (PLWH) experienced a marked increase in life expectancy but are now at higher risk for cardiovascular disease (CVD), the current leading cause of death in PLWH on cART. Although HIV preponderantly affects men over women, manifestations of HIV-related CVD differ by sex with women experiencing greater risks than men. Despite extensive investigation, the etiopathology of CVD, notably the respective contribution of viral infection and cART, remain ill-defined. However, both viral infection and cART have been reported to contribute to endothelial dysfunction, the precursor and major cause of atherosclerosis-associated CVD, through mechanisms involving endothelial cell activation, inflammation, and oxidative stress, all leading to reduced nitric oxide bioavailability. Therefore, preserving endothelial function in PLWH on cART should be a main target to reduce CVD morbidity and mortality, notably in females. People living with HIV (PLWH) now have a greater life expectancy but are at elevated risk of CVD compared to age-matched uninfected individuals, and CVD has arisen as the main cause of death in HIVinfected patients (4, 5) . Recent systematic studies have shown that the risk for CVD is 2-fold higher in PLWH compared to the general population, and HIVrelated CVD showed a 3-fold increase from 1990 to 2015 (6) . Remarkably, the rate of HIV-associated CVD is unequal between the sexes with females experiencing much greater risk for developing CVD than males (7) (8) (9) (10) (11) . Additionally, female PLWH exhibit elevated rates and risks for cardiovascular (CV) events and death compared to noninfected women (12) . Therefore, biological sex appears to be an additional risk factor to consider when evaluating the risk of HIV acquisition and manifestations of the disease. and pulmonary hypertension (PH) (13) . There is a consensus that rates of acute myocardial infarction (AMI) are elevated among PLWH. Studies from the United States and Europe confirmed the strong correlation between HIV and increased risk of AMI claiming that incident rates of AMI is greatly elevated in PLWH compared to the general population (8, (14) (15) (16) shown that AMI is more strongly associated with HIV in women than men and results from a US cohort have reported increased relative risk for the disease in women compared to men among PLWH (8) . Others have also confirmed that female PLWH are exposed to higher risk of MI than males (15, 32) . Emerging data reveals that HIV infection is also a significant risk factor for HF in women (12) . The relative risk of HF has been shown to be the highest in young people (20 to 29 years old) and in female PLWH and it displays a declining trend with age (33,34). HIV-positive women are also at a higher risk to experience stroke versus uninfected women and are at considerably greater risk for stroke and intracerebral hemorrhage than male PLWH, which collectively supports a stronger as a potential explanation for this sex-discrepancy and higher prevalence of HIV-associated CVD. Notably, studies have reported that markers of innate immune activation such as CXCL10, sCD163, and sCD14 are increased and remain elevated in cARTnaive and cART-treated women, respectively, compared to male PLWH (147, 148) . In comparison to male PLWH, women with a lower CD4þ count have higher levels of macrophage inflammatory markers including galectin-3 binding protein (Gal-3BP), sCD163, and sCD14 which is associated with greater prevalence of cIMT (149) . Similarly, increased prevalence of noncalcified coronary plaques correlates with higher monocyte activation in female compared to male PLWH and noninfected individuals, and monocyte activation was further elevated with age among women versus men PLWH (150) . Collectively, these data support a higher immune activation in females in response to HIV. The female sex hormones progesterone and estrogen may contribute to this sex (110) PI regimen or non-PI regimen a FMD, cIMT FMD impaired, cIMT increased Charakida (111) PI regimen or non-PI regimen a FMD No change in FMD Solages (112) NRTIs with one or two PIs (IDV, RTV or SQVþRTV) cIMT cIMT increased Seminari (113) cART with a PI (IDV, NFV, SQVþRTV, or LPVþRTV) PVW Arterial stiffness increased Schillaci (114) groups, limited or no access to health care, excessive smoking, and substance abuse could contribute to the above-mentioned disparities (158) (159) (160) (161) (162) . Female PLWH are often African American women who are exposed to higher risk of stroke and other CV events (159) . In this particular female population, poor economic status, barriers to access health care, and greater added relative risk of smoking ultimately lead to a higher prevalence of CVD (160, 161) . Together, these data suggest that the pathological mechanism responsible for the sex disparities in HIV- The end of AIDS: HIV infection as a chronic disease Acute coronary syndromes in patients with HIV Cardiovascular complications of HIV infection Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis Sex differences in HIV infection Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease Comparison of ischemic stroke incidence in HIV-infected and non-HIVinfected patients in a US health care system Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database HIV infection and cardiovascular disease in women HIV infection and the risk of acute myocardial infarction Increased risk of myocardial infarction in HIVinfected patients in France, relative to the general population Ischemic heart disease in HIV-infected and HIVuninfected individuals: a population-based cohort study Pulmonary hypertension in HIV infection: a prospective echocardiographic study Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis Cardiovascular disease in human immunodeficiency virus infected patients: a true or perceived risk? Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis Endothelial function and dysfunction: testing and clinical relevance HIV Proteins and endothelial dysfunction: implications in cardiovascular disease Vascular endothelial dysfunction in the wake of HIV and ART Endothelial function and cardiovascular diseases in HIV infected patient Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study Markers of endothelial dysfunction Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis? Flow mediated dilation and carotid intima media thickness: clinical markers or just research tools? Imaging of coronary atherosclerosis by computed tomography Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk Human immunodeficiency virus per se exerts atherogenic effects Endothelial cell dysfunction in HIV infection Abnormal levels of circulating adhesion molecules in HIV-1 infection with characteristic alterations in opportunistic infections Circulating cell adhesion molecules in HIV1-infected patients as indicator markers for AIDS progression Plasma levels of soluble CD14 independently predict mortality in HIV infection Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients monocyte activation Inflammatory markers associated with subclinical coronary artery disease: the multicenter AIDS Cohort Study Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults Progression of atherosclerosis as assessed by carotid intimamedia thickness in patients with HIV infection Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men Low CD4þ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers Caspase-1 activation is related with HIV-associated atherosclerosis in an HIV transgenic mouse model and HIV patient cohort Characterization of neuropathology in the HIV-1 transgenic rat at different ages HIV increases basal metabolic rate, impairs endothelial function and elevates blood pressure in male and female mice Human immunodeficiency virus transgenic rats exhibit pulmonary hypertension Non-human primate models of SIV infection and CNS neuropathology Caspase-1-associated immune activation in an accelerated SIV-infected rhesus macaque model Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration NOX1, 2, 4, 5: counting out oxidative stress NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium Elevated levels of tumor necrosis factor alpha (TNF-alpha) in human immunodeficiency virus type 1-transgenic mice: prevention of death by antibody to TNFalpha Microbial translocation and cardiometabolic risk factors in HIV infection CCR5 inhibition prevents cardiac dysfunction in the SIV/macaque model of HIV HIV: cell binding and entry. Cold Spring Harb Perspect Med Targeting CCR5 trafficking to inhibit HIV-1 infection CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 Tcells, and decreases SARS-CoV2 RNA in plasma by day 14 Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice HIV protease inhibitor ritonavir impairs endothelial function via reduction in adipose mass and endothelial leptin receptordependent increases in NADPH oxidase 1 (Nox1), C-C chemokine receptor type 5 (CCR5), and inflammation HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(þ) cells by a tumor necrosis factor-related apoptosis-induced ligandmediated mechanism HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappa B activation Migration of V delta 1 and V delta 2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1 Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice Immunological and virological studies of natural SIV infection of disease-resistant nonhuman primates HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells HIV Tat induces expression of ICAM-1 in HUVECs: implications for miR-221/-222 in HIVassociated cardiomyopathy The role of ERK1/2 signaling pathway in Nef protein upregulation of the expression of the intercellular adhesion molecule 1 in endothelial cells HIV-1 Tat protein-induced VCAM-1 expression in human pulmonary artery endothelial cells and its signaling Endothelial function in HIVinfected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy Endothelial function in HIV-infected persons Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients Cross-sectional study of endothelial function in HIV-infected patients in Brazil Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia HIV infection, antiretroviral therapy, and measures of endothelial function, inflammation, metabolism, and oxidative stress Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) study 5152s Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy Association of highly active antiretroviral therapy with increased arterial stiffness in patients infected with human immunodeficiency virus Associations between HIV infection and subclinical coronary atherosclerosis Endothelial activation and cardiometabolic profiles of treated and never-treated HIV infected Africans HIV disease is associated with increased biomarkers of endothelial dysfunction despite viral suppression on long-term antiretroviral therapy in Botswana D-Dimer levels and traditional risk factors are associated with incident hypertension among HIVinfected individuals initiating antiretroviral therapy in Uganda HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction Plasma levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIVnegative healthy controls Markers of coagulation and inflammation often remain elevated in ARTtreated HIV-infected patients Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1 Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebocontrolled trial Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: effects of antiretroviral therapy and adipose tissue distribution Ageassociated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women Cutting edge: progesterone regulates IFN-alpha production by plasmacytoid dendritic cells Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-alpha production in women Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1 treatment-naive human immunodeficiency virus-1 infected patients: pooled analyses of the STARTMRK and QDMRK studies Sexrelated differences in inflammatory and immune activation markers before and after combined antiretroviral therapy initiation Biomarkers of inflammation in HIV-infected Peruvian men and women before and during suppressive antiretroviral therapy A decade of racial and ethnic stroke disparities in the United States Stroke incidence is highest in women and non-Hispanic blacks living with HIV in the Barriers to access to care reported by women living with HIV across 27 countries Sex differences in tobacco use among persons living with HIV/AIDS: a systematic review and meta-analysis Substance abuse treatment in persons with HIV/AIDS: challenges in managing triple diagnosis KEY WORDS combination antiretroviral therapy, endothelial dysfunction, HIV, sex differences